Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 8, pp 2708–2716 | Cite as

Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center

  • Jonghun J. Lee
  • Peter T. W. Kim
  • Sandra Fischer
  • Scott Fung
  • Steven Gallinger
  • Ian McGilvray
  • Carol-anne Moulton
  • Alice C. Wei
  • Paul D. Greig
  • Sean P. Cleary
Hepatobiliary Tumors

Abstract

Background

Hepatitis B (HBV) and hepatitis C (HCV) are well-recognized risk factors for hepatocellular carcinoma (HCC). The characteristics and clinical outcomes of HCC arising from these conditions may differ. This study was conducted to compare the outcomes of HCC associated with HBV and HCV after liver resection.

Methods

Of 386 liver resections for HCC performed between July 1992 and April 2011, 181 patients had HBV and 74 patients had HCV. Patients with HBV/HCV coinfections (n = 20), non-HBV/HCV etiology (n = 94), and postoperative death within 3 months (n = 17) were excluded. Patient, tumor characteristics, and perioperative and oncologic outcomes were compared between patients with HBV and HCV.

Results

The patients with HBV had better overall survival (OS) than patients with HCV (68 vs. 59 months, p = 0.03); however, there was no difference in recurrence-free survival (RFS) between the groups (44 vs. 45 months, p = 0.1). The factors predictive of OS based on multivariate analyses included: vascular invasion [p < 0.01, hazard ratio (HR) = 3.4], Child-Pugh Score (p < 0.01, HR = 4.8), and underlying liver disease (HCV vs HBV) (p = 0.01, HR = 1.9). Vascular invasion and tumor number (p < 0.01, HR = 2.3 and p < 0.01, HR = 2.1) were independent predictors of RFS.

Conclusions

OS but not RFS after liver resection for HCC is better in patients with HBV than HCV. This survival advantage for HBV patients may be due to differences in tumor biology and outcomes after disease recurrence.

Keywords

Overall Survival Liver Resection Vascular Invasion Good Overall Survival Hepatic Venous Pressure Gradient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of Interest

The authors declare no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. Cancer J Clin 2011;61:69.CrossRefGoogle Scholar
  2. 2.
    Perz JF, Armstrong GL, Farrington LA, et al. The Contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer world wide. J Hepatol 2006;45:529–38. PubMedCrossRefGoogle Scholar
  3. 3.
    Parkin DM. The global health burden of infections-associated cancers in the year 2002. Int J cancer 2006;118:3030–44.PubMedCrossRefGoogle Scholar
  4. 4.
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817.PubMedCrossRefGoogle Scholar
  5. 5.
    Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372.PubMedCrossRefGoogle Scholar
  6. 6.
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27.PubMedCrossRefGoogle Scholar
  7. 7.
    Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004;12:96–102.PubMedCrossRefGoogle Scholar
  8. 8.
    Kao KY, Su CW, Chau GY, et al. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 2011;35:858–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim MY, Cho MY, Baik SK, et al. Histological subclassifications of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011;55:1004–09.PubMedCrossRefGoogle Scholar
  11. 11.
    Dindo D, Demartines N, Clavien P. Classification of surgical complications. Ann Surg 2004;240:205–13.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Tan CH, Low SC, Thng CH. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol 2011;2011:1–11.CrossRefGoogle Scholar
  13. 13.
    Haratake J, Takeda S, Kasai T, et al. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 2003;72:1178–83.CrossRefGoogle Scholar
  14. 14.
    Li Q, Li H, Qin Y, Wang P, Hao X. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. Hepatology 2007;22:1936–41.Google Scholar
  15. 15.
    Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997;79:1509–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771–79.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004;8:794–04.PubMedCrossRefGoogle Scholar
  18. 18.
    Roayaie S, Haim MB, Emre S, et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000;7:764–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding transcriptional activity and association with transcription factor ERCC3. Proc Natl Acad Sci 1994;91:2230–34.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Truant R, Antunovic J, Greenblatt J, et al. Direct interaction of the hepatitis B virus HBX protein with p53 leads to inhibition by HBX of p53 response element-directed transactivation. J Virol 1995;69:1107–14.Google Scholar
  21. 21.
    Castells L, Vargas V, Gonzalez A, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995;15:159–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010;75:165–72.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Jonghun J. Lee
    • 1
  • Peter T. W. Kim
    • 4
  • Sandra Fischer
    • 2
  • Scott Fung
    • 3
  • Steven Gallinger
    • 1
  • Ian McGilvray
    • 1
  • Carol-anne Moulton
    • 1
  • Alice C. Wei
    • 1
  • Paul D. Greig
    • 1
  • Sean P. Cleary
    • 1
  1. 1.Department of Surgery, 10EN216 Toronto General HospitalUniversity Health Network, University of TorontoTorontoCanada
  2. 2.Department of PathologyUniversity Health Network, University of TorontoTorontoCanada
  3. 3.Department of GastroenterologyUniversity Health Network, University of TorontoTorontoCanada
  4. 4.Abdominal Transplantation and Hepatobiliary SurgeryBaylor University Medical CenterDallasUSA

Personalised recommendations